efgartigimod alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
immunomodulators, both stimulant/suppressive and stimulant 5499 1821402-21-4

Description:

MoleculeDescription

Molfile

Synonyms:

  • efgartigimod alfa
  • efgartigimod alfa (genetical recombination)
  • efgartigimod alfa-fcab
  • vyvgart
  • ARGX-113
Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 21, 2018 EMA Argenx
Dec. 12, 2021 FDA ARGENX BV
Jan. 20, 2022 PMDA Argenx Japan K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Symptom recurrence 96.73 63.72 12 43 1798 63487169

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Symptom recurrence 82.89 45.17 11 69 2303 79742005
Myasthenia gravis crisis 45.78 45.17 6 74 1105 79743203

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA58 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA EPC N0000194004 Neonatal Fc Receptor Blocker
FDA MoA N0000194005 Neonatal Fc Receptor Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Immune thrombocytopenia indication 2897005 DOID:1587
Myasthenia gravis indication 91637004 DOID:437




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
IgG receptor FcRn large subunit p51 Membrane receptor INHIBITOR Kd 8.07 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL4297551 ChEMBL_ID
C000718373 MESH_SUPPLEMENTAL_RECORD_UI
9777 IUPHAR_LIGAND_ID
DB15270 DRUGBANK_ID
018912 NDDF
4041066 VANDF
4041067 VANDF
D11876 KEGG_DRUG
C5139924 UMLSCUI
10455 INN_ID
2587717 RXNORM
354396 MMSL
40184 MMSL
40196 MMSL
d09842 MMSL
961YV2O515 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VYVGART HUMAN PRESCRIPTION DRUG LABEL 1 73475-3041 INJECTION 20 mg INTRAVENOUS BLA 28 sections
VYVGART HUMAN PRESCRIPTION DRUG LABEL 1 73475-3041 INJECTION 20 mg INTRAVENOUS BLA 28 sections
VYVGART Hytrulo HUMAN PRESCRIPTION DRUG LABEL 2 73475-3102 INJECTION, SOLUTION 180 mg SUBCUTANEOUS BLA 28 sections